Daiichi Sankyo Ya Sanar da Sakamako na Karan Gwajin Alurar riga kafi

Tokyo, Japan - (Nuwamba 15, 2022) - Daiichi Sankyo (TSE: 4568) a yau ta sanar da cewa a cikin gwaji don kimanta inganci da amincin allurar rigakafi tare da DS-5670, rigakafin mRNA daga cutar sankara na coronavirus (COVID). -19) Daiichi Sankyo ne ya haɓaka (bayan nan, gwaji na rigakafin ƙararrawa), an cimma maƙasudin ƙarshen farko.Gwajin rigakafin haɓaka ya haɗa da kusan 5,000 ƙoshin lafiya manya da tsofaffin batutuwa na Jafananci waɗanda suka kammala jerin farko (masu allurai biyu) na rigakafin mRNA da aka amince da su a Japan aƙalla watanni shida kafin shiga.A cikin Janairu 2022, an fara gwajin a matsayin gwaji na lokaci 1/2/3 don kimanta inganci da amincin allurar rigakafin haɓaka tare da DS-5670 ta amfani da allurar mRNA da aka amince da ita a Japan a matsayin kulawa.GMFR na neutralizing antibody titer a kan SARS-CoV-2 (na asali iri) a cikin jini makonni hudu bayan maganin rigakafi, farkon ƙarshen gwajin rigakafin, ya nuna babban bayanai da rashin ƙarancin DS-5670 ga allurar mRNA ( nau'in asali) an amince da shi a Japan, cimma manufar da aka yi niyya.Ba a gano matsalolin tsaro ba.Za a gabatar da cikakkun sakamakon gwajin rigakafin masu haɓakawa a taron ilimi da kuma cikin takaddun bincike.Dangane da sakamakon gwaji, Daiichi Sankyo zai ci gaba da shirye-shiryen sabon aikace-aikacen magani na maganin rigakafin mRNA a cikin Janairu 2023. Bugu da ƙari, Daiichi Sankyo yana shirin gudanar da gwajin asibiti na maganin rigakafi na bivalent na asali na asali da Omicron damuwa da sabon coronaviruses, wanda ke ci gaba da canzawa.Daiichi Sankyo zai yi ƙoƙari don ƙarfafa ci gaban rigakafin mRNA da tsarin samar da shi don tabbatar da ingantaccen wadata a lokuta na yau da kullun tare da samar da gaggawar samar da alluran rigakafi a yayin bullar cututtukan da suka kunno kai da sake bullowa.

Game da DS-5670 DS-5670 maganin mRNA ne akan COVID-19 ta amfani da sabuwar fasahar isar da acid nucleic acid wanda Daiichi Sankyo ya gano, wanda aka ƙera don samar da ƙwayoyin rigakafi ga yankin mai ɗaure mai karɓa (RBD) na furotin mai karu na sabon coronavirus, don haka ana tsammanin samun ingantaccen rigakafin COVID-19 da aminci na 2.Bugu da ƙari, Daiichi Sankyo yana nufin rigakafin mRNA waɗanda za a iya rarraba su a cikin kewayon zafin jiki mai sanyi (2-8°C)